April 2026: Wegovy HD Approved, Hims Pivots to Branded, and Medicare GLP-1 Coverage Begins

April 2026 marks an inflection point for the GLP-1 market. Three months of rapid-fire developments — from a blockbuster Novo-Hims settlement to Medicare finally covering weight loss drugs — have fundamentally changed the landscape. Here’s everything that happened and what it means for your provider choices.

The Biggest Headlines

Wegovy HD (7.2mg) — A Stronger Dose Is Here

On March 19, 2026, the FDA approved Wegovy HD — a higher 7.2mg dose of semaglutide — under the National Priority Review Voucher pilot. This is the most potent semaglutide injection available:

• 20.7% average weight loss at 72 weeks (vs. 17.5% for the standard 2.4mg dose)
• Same once-weekly injection, same gradual titration — just a higher maintenance dose
• Expected to launch through all existing Wegovy channels (pharmacies, telehealth, NovoCare) in April 2026

What this means: Patients who’ve plateaued on Wegovy 2.4mg now have a branded escalation option before switching to tirzepatide. This narrows the efficacy gap between semaglutide (~21% with HD) and tirzepatide (~21% at 15mg).

Hims Settles with Novo, Becomes Authorized Seller

In a stunning reversal, Hims & Hers went from being sued by Novo Nordisk to partnering with them — all in one month:

• February 9: Novo Nordisk sued Hims for patent infringement over compounded semaglutide
• March 9: Settlement reached — Novo dismissed the lawsuit
• The deal: Hims agreed to stop promoting compounded semaglutide and became an authorized seller of branded Wegovy and Ozempic (injections and pills)
• HIMS stock surged 46% on the settlement news

Hims also announced a $1.15 billion acquisition of Australia’s Eucalyptus (Juniper, Pilot, Kin brands) on February 19 — the biggest telehealth M&A move this year, expanding into AU, UK, DE, JP, and CA.

What’s still unresolved: The SEC investigation into Hims’ GLP-1 business disclosures remains open, and the HHS/DOJ referral is still pending. HIMS stock is still down ~42% YTD despite the Novo deal pop. We’re keeping Hims out of our top rankings until those investigations conclude, but the branded pivot removes the IP/regulatory risk that triggered our March downgrade.

Medicare GLP-1 Coverage Starts — $50/Month

After years of excluding weight loss drugs, Medicare is finally covering GLP-1 medications:

• Zepbound Medicare coverage at $50/month max copay begins April 1, 2026 (via multi-dose KwikPen)
• Medicare GLP-1 Bridge Program launches July 2026 — all eligible Part D beneficiaries pay max $50/month for GLP-1s
• BALANCE Model starts accepting state Medicaid agencies in May 2026, Medicare Part D plans in January 2027
• The 2026 Medicare $2,100 annual out-of-pocket cap on Part D drugs also helps limit total exposure

What this means: For the 67 million Americans on Medicare, branded GLP-1s just became dramatically more affordable. The $50/month copay is competitive with compounded options — and comes with full FDA approval and manufacturer quality assurance.

Orforglipron — Lilly’s Oral Pill Faces FDA Decision

Eli Lilly’s orforglipron — a once-daily oral GLP-1 pill — has its PDUFA date on April 10, 2026. If approved:

• Targeted consumer price: $149/month (matching Wegovy pill pricing)
• Medicare pricing: $50/month (under Lilly’s government agreement)
• First oral GLP-1 pill not from Novo Nordisk — introduces real competition in the oral segment
• Small molecule (not a peptide), so potentially easier to manufacture and scale

This would give patients two oral GLP-1 options: Wegovy pill (semaglutide, Novo) and orforglipron (Lilly). Competition in the oral space should keep prices down.

Provider Landscape Changes

Lilly Employer Connect Launches

On March 5, 2026, Eli Lilly launched Lilly Employer Connect — a platform that bypasses PBMs entirely and lets employers offer Zepbound coverage directly through 15+ independent program administrators. Zepbound KwikPen is available to network pharmacies at $449 for all doses.

This is significant because PBM formulary restrictions have been the #1 barrier to Zepbound insurance coverage. Employers can now offer it directly.

Oral Wegovy Now Broadly Available — But $149 Intro Price Ends April 15

The Wegovy pill (oral semaglutide) is now available at 70,000+ U.S. pharmacies including CVS and Costco, plus all major telehealth partners (Ro, LifeMD, WeightWatchers, GoodRx, knownwell, eMed, and now Hims). Self-pay pricing:

• Starting doses (1.5mg, 4mg): $149/month through April 15 only, then increases to $199/month
• Maintenance doses (9mg, 25mg): $299/month

If you’ve been considering the oral pill, now is the time — the introductory $149/month starter dose pricing expires on April 15, 2026. After that, expect $199/month for starting doses.

FDA Crackdown on Compounders Continues

The FDA sent 30 new warning letters to telehealth companies in late February (made public March 3), bringing the total to 80+ since September 2025. Key enforcement points:

• Mass-marketed compounded semaglutide and tirzepatide are no longer legally allowed (shortage ended)
• Companies cannot compare compounded drugs to FDA-approved versions or claim the same active ingredient
• HHS has referred certain companies to the DOJ for investigation
• Despite the crackdown, reports indicate compounded GLP-1s are still widely available — enforcement hasn’t caught up with the market yet

Our take: The compounded market is living on borrowed time. Between Novo’s 2027 price cuts, Medicare coverage, and escalating FDA enforcement, the economic case for compounded GLP-1s weakens every month. We continue to include compounded providers in our rankings where they offer legitimate value, but recommend patients have a branded backup plan.

What’s Coming Next

Retatrutide — The Triple Agonist

Lilly’s next-generation retatrutide (GLP-1 + GIP + glucagon triple agonist) posted Phase 3 results on March 19:

• 28.7% average weight loss at 68 weeks in the TRIUMPH-4 trial (71 lbs average)
• A1C reductions up to 2.0% in the TRANSCEND-T2D-1 diabetes trial
• Seven more Phase 3 readouts expected throughout 2026
• If approved (likely 2027-2028), this would be the most effective weight loss medication ever

Insurance Coverage Expanding (Slowly)

• North Dakota became the first state to mandate insurance coverage for GLP-1 obesity treatment
• 44% of large employers (500+ employees) now cover weight loss medications, up from prior years
• Mixed signals: Some employers are cutting GLP-1 coverage due to higher-than-expected utilization costs. Mass General Brigham dropped GLP-1 obesity coverage for individual/small employer plans as of January 2026

Updated Pricing Snapshot (April 2026)

Option	Monthly Cost	Status
Wegovy pill (self-pay)	$149-299/mo	Broadly available
Wegovy injection (self-pay)	$199-499/mo	Available
Wegovy HD 7.2mg	TBD	Launching April 2026
Zepbound KwikPen (self-pay)	$299-449/mo	Available
Zepbound (Medicare)	$50/mo copay	Starting April 2026
TrumpRx.gov	~$350/mo	Live
Compounded semaglutide	$45-299/mo	Regulatory risk
Orforglipron (if approved)	~$149/mo	PDUFA April 10

Rankings Impact

Our provider rankings reflect these changes:

• Hims remains excluded from top rankings pending SEC/DOJ resolution, though the branded pivot is a positive signal
• Medicare-friendly providers (knownwell, Calibrate) get a boost as $50/month coverage begins
• Compounded-only providers face increasing headwinds — we’re flagging regulatory risk more prominently
• Ro and LifeMD remain our top picks for most patients — both offer branded + compounded options with strong clinical support

See our full Best GLP-1 Providers rankings, updated for April 2026.

Last updated: April 1, 2026. The GLP-1 market is moving fast — always verify pricing and availability with your provider.